KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Abbott Laboratories (ABT) Interest & Investment Income (2016 - 2026)

Abbott Laboratories' Interest & Investment Income history spans 18 years, with the latest figure at $106.0 million for Q1 2026.

  • On a quarterly basis, Interest & Investment Income rose 29.27% to $106.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $332.0 million, a 4.05% decrease, with the full-year FY2025 number at $308.0 million, down 10.47% from a year prior.
  • Interest & Investment Income hit $106.0 million in Q1 2026 for Abbott Laboratories, up from $78.0 million in the prior quarter.
  • Over the last five years, Interest & Investment Income for ABT hit a ceiling of $106.0 million in Q1 2026 and a floor of $14.0 million in Q1 2022.
  • Historically, Interest & Investment Income has averaged $78.0 million across 5 years, with a median of $82.0 million in 2024.
  • Biggest five-year swings in Interest & Investment Income: soared 700.0% in 2022 and later fell 20.79% in 2024.
  • Tracing ABT's Interest & Investment Income over 5 years: stood at $88.0 million in 2022, then grew by 1.14% to $89.0 million in 2023, then rose by 2.25% to $91.0 million in 2024, then dropped by 14.29% to $78.0 million in 2025, then surged by 35.9% to $106.0 million in 2026.
  • Business Quant data shows Interest & Investment Income for ABT at $106.0 million in Q1 2026, $78.0 million in Q4 2025, and $77.0 million in Q3 2025.